The global Immunoassay Market is growing as healthcare providers increasingly rely on accurate, rapid, and reliable diagnostic technologies to detect diseases and monitor patient health. Immunoassays are laboratory tests that use the specific interactions between antibodies and antigens to identify and measure substances such as hormones, proteins, drugs, and infectious agents in biological samples.
According to Kings Research, the global immunoassay market was valued at USD 33.83 billion in 2023 and is estimated to reach USD 35.28 billion in 2024. The market is projected to reach USD 51.90 billion by 2031, registering a compound annual growth rate of 5.67% during the forecast period.
The increasing prevalence of chronic diseases, growing demand for early diagnosis, and expanding use of automated laboratory equipment are supporting market growth. Immunoassays are widely used in infectious disease testing, oncology, cardiology, endocrinology, therapeutic drug monitoring, and autoimmune disease diagnosis.
Technological advancements in chemiluminescence, enzyme-linked immunosorbent assays, rapid diagnostic tests, and automated analyzers are improving testing efficiency and analytical sensitivity. The growing adoption of personalized medicine and point-of-care diagnostics is further expanding the role of immunoassays across hospitals, clinical laboratories, research institutions, and home healthcare settings.
Rising Prevalence of Chronic and Infectious Diseases
The increasing burden of chronic and infectious diseases is one of the primary factors driving the immunoassay market. Conditions such as cancer, diabetes, cardiovascular disorders, thyroid dysfunction, and autoimmune diseases require reliable diagnostic methods for early detection, treatment planning, and continuous monitoring.
Immunoassays help healthcare professionals identify disease-associated biomarkers and evaluate changes in patient health. For example, cardiac biomarker tests can support the assessment of heart-related conditions, while hormone assays help diagnose endocrine disorders. Oncology-related immunoassays can measure specific biomarkers that assist clinicians in evaluating certain cancers and monitoring treatment response.
Infectious disease testing represents another major application. Immunoassays can detect antigens produced by pathogens or antibodies generated by the immune system in response to infection. These tests are used in the diagnosis of several viral and bacterial diseases, depending on the assay design and intended use.
According to Kings Research, infectious disease testing accounted for 24.02% of the immunoassay market in 2023. The demand for reliable diagnostic testing, improved disease surveillance, and timely clinical decision-making is expected to support this segment.
The expansion of screening programs and greater awareness of preventive healthcare are also increasing demand for immunoassay-based testing across healthcare systems.
Growing Elderly Population Supports Diagnostic Demand
Population aging is creating additional opportunities for immunoassay manufacturers. Older adults are more likely to experience chronic conditions that require regular screening, diagnosis, and treatment monitoring.
According to the World Health Organization, approximately one in six people worldwide is expected to be aged 60 years or older by 2030. The global population in this age group is projected to reach approximately 2.1 billion by 2050.
This demographic shift is increasing the need for diagnostic services related to cardiovascular diseases, cancer, diabetes, kidney disorders, and neurodegenerative conditions. Immunoassays can support these services by measuring disease-related biomarkers and monitoring changes over time.
In January 2025, Beckman Coulter Diagnostics announced new research-use-only blood-based biomarker immunoassays for neurodegenerative disease research. The assays target biomarkers such as phosphorylated tau 217, glial fibrillary acidic protein, neurofilament light chain, and APOE-related markers.
These developments reflect growing interest in blood-based biomarkers for neurological research. As scientific evidence and clinical validation advance, immunoassay technologies may contribute to the development of less invasive approaches for investigating neurological disorders.
Reagents and Kits Remain the Leading Product Segment
By product, the immunoassay market is divided into reagents and kits and analyzers. Reagents and kits generated USD 19.21 billion in revenue in 2023, making them the leading product category.
Reagents and kits contain the biological and chemical components required to perform immunoassays. Their demand is closely linked to the volume of diagnostic tests conducted by hospitals, clinical laboratories, research organizations, and pharmaceutical companies.
These products include enzyme-linked immunosorbent assay reagents, chemiluminescent immunoassay kits, immunofluorescence reagents, rapid-test kits, ELISpot reagents, and Western blot-related products.
Diagnostic laboratories frequently require recurring supplies of reagents and consumables to maintain routine testing operations. The increasing volume of laboratory tests and the expansion of automated diagnostic platforms therefore support continued demand.
The reagents and kits segment is projected to reach USD 29.17 billion by 2031. Growth is expected to be supported by the increasing prevalence of chronic diseases, wider screening coverage, and continued development of tests targeting new biomarkers.
Analyzers also play an important role by automating sample processing, reagent handling, measurement, and result generation. Open-ended systems can accommodate assays from multiple sources, whereas closed-ended systems generally operate with manufacturer-specific reagents and testing platforms.
Enzyme Immunoassays Lead Technology Adoption
The immunoassay market includes enzyme immunoassays, rapid tests, radioimmunoassays, and other technologies. Enzyme immunoassays accounted for 39.33% of the market in 2023, according to Kings Research, and are projected to reach USD 20.30 billion by 2031.
Enzyme-linked immunosorbent assays, commonly known as ELISA, are widely used because they can detect specific biological substances with high analytical sensitivity and are adaptable to numerous applications.
These assays are used in infectious disease diagnosis, hormone testing, allergy evaluation, autoimmune disease research, and biomarker analysis. Their established laboratory workflows and availability in different formats make them suitable for routine testing and specialized research.
Chemiluminescence-based immunoassays are also gaining importance because they can provide sensitive measurements and support high-throughput automated testing. These systems are particularly valuable for laboratories that process large numbers of samples and require consistent turnaround times.
Rapid immunoassay tests offer advantages when results are needed quickly or laboratory infrastructure is limited. Depending on the test, they can support screening and preliminary assessment in clinics, emergency departments, community healthcare facilities, and other point-of-care environments.
The choice of technology depends on the target analyte, required sensitivity, sample type, testing volume, cost, and intended clinical application.
Automation and High-Throughput Testing Improve Laboratory Efficiency
Automation is transforming the immunoassay market by helping laboratories manage increasing test volumes while maintaining consistent analytical performance.
Automated immunoassay analyzers can process multiple samples, manage reagent dispensing, perform measurements, and transmit results to laboratory information systems. These capabilities reduce repetitive manual work and can improve workflow efficiency.
In May 2023, Beckman Coulter introduced its DxI 9000 Access Immunoassay Analyzer, designed to support high laboratory productivity, analytical sensitivity, and operational reliability. The system incorporated technologies intended to reduce routine maintenance and improve laboratory uptime.
In May 2024, Siemens Healthineers introduced four additional blood biomarkers for an automated inflammation testing panel on its IMMULITE 2000 and 2000 XPi systems. The panel expanded testing options for evaluating inflammatory conditions.
Such developments demonstrate how manufacturers are improving analyzer capabilities while expanding the range of available assays.
Automation can be particularly valuable for large clinical laboratories, where delays may affect diagnostic workflows and patient management. However, successful implementation also requires appropriate staff training, equipment maintenance, quality-control procedures, and reliable integration with laboratory information systems.
Growing Importance of Oncology and Cardiology Applications
Oncology and cardiology are important application areas for immunoassay technologies. In oncology, immunoassays can measure selected tumor-associated biomarkers, support certain diagnostic assessments, and help monitor disease progression or treatment response. Their usefulness depends on the specific biomarker and clinical context, and results generally need to be interpreted alongside other medical findings.
Cardiology-related immunoassays measure biomarkers that can help clinicians assess heart conditions. Tests for cardiac troponins and other relevant markers are commonly used in evaluating suspected cardiac injury, while assays for natriuretic peptides can support the assessment of heart failure.
In May 2024, Beckman Coulter received U.S. Food and Drug Administration clearance for its Access NT-proBNP assay, designed to support heart failure assessment on the DxI 9000 Immunoassay Analyzer.
Endocrinology is another significant application, with immunoassays widely used to measure thyroid hormones, reproductive hormones, and other substances involved in hormonal regulation.
Therapeutic drug monitoring provides further opportunities by helping healthcare professionals measure drug concentrations in selected cases where monitoring can support treatment decisions. These applications demonstrate the importance of immunoassays in routine diagnostics as well as specialized clinical care.
Point-of-Care Testing Expands Access to Diagnostics
Point-of-care testing is becoming increasingly important as healthcare providers seek faster diagnostic results closer to patients. Traditional laboratory testing may require sample transportation, centralized processing, and additional waiting time before results become available.
Rapid immunoassay systems can help reduce these delays in suitable applications. They are used in clinics, emergency departments, community healthcare settings, and other environments where timely results can support clinical decisions.
In September 2023, QuidelOrtho announced that its Sofia 2 SARS Antigen+ fluorescent immunoassay received a Clinical Laboratory Improvement Amendments waiver from the FDA. This enabled eligible testing sites to use the test under the applicable waived-testing framework.
The broader development of compact analyzers, simplified workflows, and rapid diagnostic kits is creating opportunities to expand immunoassay testing beyond centralized laboratories.
However, point-of-care tests must still meet relevant performance and quality requirements. Appropriate training, sample handling, result interpretation, and quality-control procedures remain important to ensure reliable testing.
Regulatory Requirements and Quality Assurance
Regulatory compliance is a major consideration in the immunoassay market because diagnostic tests can directly influence medical decisions. Manufacturers must demonstrate that their products meet the applicable requirements for analytical performance, clinical validity where required, manufacturing quality, and intended use.
In the United States, the FDA regulates applicable in vitro diagnostic devices, while the CLIA framework establishes requirements for covered human laboratory testing. The exact regulatory pathway depends on the product and its intended use.
In the European Union, in vitro diagnostic devices are subject to the In Vitro Diagnostic Medical Devices Regulation. Manufacturers must address applicable requirements involving performance evaluation, conformity assessment, quality management, and post-market surveillance.
In India, the Central Drugs Standard Control Organisation oversees relevant medical devices and diagnostic products under the country’s applicable regulatory framework.
These requirements can increase development costs and extend commercialization timelines. Manufacturers must also maintain consistent reagent quality, validate assay performance, monitor product stability, and address manufacturing changes carefully.
Regulatory compliance and reliable quality assurance are essential for maintaining confidence among healthcare professionals, laboratories, and patients.
Regional Analysis of the Immunoassay Market
North America held the largest share of the global immunoassay market in 2023, accounting for 34.54% and representing approximately USD 11.68 billion in revenue. The region benefits from advanced healthcare infrastructure, high diagnostic testing volumes, substantial healthcare expenditure, and strong investment in research and development.
The presence of established diagnostic manufacturers, well-developed laboratory networks, and widespread adoption of automated testing technologies further supports regional growth. Demand for early disease detection and chronic disease monitoring also contributes to market expansion.
Asia Pacific is expected to record a compound annual growth rate of 5.76% during the forecast period, with the market projected to reach USD 11.94 billion by 2031.
The region’s growth is supported by expanding healthcare infrastructure, increasing awareness of preventive screening, a growing elderly population, and rising demand for diagnostic services. China, India, Japan, South Korea, and Australia are important markets with diverse healthcare systems and diagnostic needs.
In March 2024, Sysmex Corporation introduced six additional gynecological and gonadal hormone immunoassay kits in Japan, expanding the testing capabilities of its HISCL series.
Europe also represents a significant market, supported by established clinical laboratories, public healthcare systems, and demand for advanced diagnostic technologies. Meanwhile, healthcare infrastructure development and improving access to laboratory testing are creating opportunities across Latin America and the Middle East and Africa.
Competitive Landscape and Industry Developments
The immunoassay market includes diagnostic equipment manufacturers, laboratory technology providers, reagent developers, and biotechnology companies. Competition is shaped by analytical sensitivity, test accuracy, automation, throughput, turnaround time, instrument reliability, and the breadth of available assays.
Key companies operating in the market include Abbott, Siemens Healthineers, Beckman Coulter, bioMérieux, QuidelOrtho, Sysmex Corporation, Bio-Rad Laboratories, Roche, BD, Thermo Fisher Scientific, Merck KGaA, Revvity, Shenzhen Mindray Bio-Medical Electronics, and Meso Scale Diagnostics.
In February 2023, Siemens Healthineers and Unilabs announced a partnership under which Unilabs planned to invest in Siemens Healthineers technology, including the acquisition of more than 400 laboratory analyzers. The collaboration was intended to modernize laboratory infrastructure and improve diagnostic services across Unilabs’ network.
In October 2024, bioMérieux announced the CE marking of its VIDAS Vitamin B12 Total test, expanding its automated immunoassay portfolio for measuring vitamin B12 levels in human serum or plasma.
In January 2025, bioMérieux announced its acquisition of SpinChip Diagnostics, a Norwegian company developing a rapid immunoassay platform. The acquisition was intended to strengthen bioMérieux’s point-of-care diagnostic capabilities, including testing for acute conditions.
These developments highlight continued investment in automated testing, rapid diagnostics, assay expansion, and laboratory efficiency.
Future Outlook of the Immunoassay Market
The future of the immunoassay market will be influenced by automation, biomarker discovery, point-of-care testing, personalized medicine, and advances in diagnostic technologies.
Manufacturers are expected to continue developing assays with improved sensitivity, broader testing capabilities, and shorter turnaround times. Automation and laboratory connectivity will remain important as healthcare providers seek to manage increasing test volumes with consistent quality.
The growth of precision medicine is likely to increase demand for tests that measure specific biomarkers and help characterize individual disease conditions. Research into blood-based biomarkers for cancer and neurological disorders may also create new opportunities, subject to clinical validation and regulatory approval.
Point-of-care platforms could improve access to testing in decentralized healthcare environments, while advanced laboratory analyzers will continue to serve facilities processing large numbers of samples.
At the same time, regulatory complexity, equipment costs, reagent supply, and the need for rigorous quality control will remain important challenges. Companies that combine reliable assay performance with efficient workflows and broad diagnostic portfolios are likely to remain competitive.
Conclusion
The Immunoassay Market is an essential part of modern diagnostic healthcare, supporting the detection and monitoring of infectious diseases, cancer, cardiovascular conditions, endocrine disorders, and other medical conditions. According to Kings Research, the market is projected to increase from USD 35.28 billion in 2024 to USD 51.90 billion by 2031, registering a compound annual growth rate of 5.67%.
Reagents and kits remain the leading product segment, while enzyme immunoassays continue to play an important role in clinical diagnostics. Automation, point-of-care testing, and advances in biomarker detection are expanding the range of immunoassay applications.
North America currently leads the market, while Asia Pacific is expected to experience steady growth as healthcare infrastructure and diagnostic access improve. Regulatory requirements, analytical quality, and manufacturing consistency will remain important considerations for market participants.
As healthcare systems increasingly prioritize early diagnosis, reliable monitoring, and efficient laboratory operations, immunoassay technologies are expected to remain central to clinical diagnostics and the continuing development of modern healthcare.
